Topic Highlight
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. May 28, 2006; 12(20): 3180-3185
Published online May 28, 2006. doi: 10.3748/wjg.v12.i20.3180
Table 1 Classification of pancreatic endorcrine tumous
TumorHormone producedPercent malignantClinical features5 yr survivalLocalizationTreatment
InsulinomaInsulin proinsulin10%Hypoglycemia, neuroglycopenic symptoms97%EUS, intraoperative ultrasoundSurgical resection, chemotherapy, dextrose
GastrinomaGastrin60%-90%Peptic ulcer disease, diarrhea60%-70%SRS, SPECT, EUSSurgical resection, PPI, somatostatin
GlucagonomaGlucagon50%-90%Necrolytic migratory erythema, diabetes, DVT, depression50%-60%CT w/contrast, EUSSurgical resection, nutritional support, somatostatin, chemotherapy, insulin
VIPomaVasoactive intestinal peptide40%-70%Secretory diarrhea, hypokalemia, achlorhydria50%CT Scan, SRSSomatostatin, correction ofelectrolytes, hydration, surgical resection
SomatostatinomaSomatostatin70%-80%DM, cholelithiasis, steatorrhea40%CT, EUS, SRSSurgical resection chemotherapy, somatostatin
Non-functional tumorsPancreatic polypeptide60%-80%Abdominal pain, weight loss, jaundice50%CT, MRISurgical resection